Negative / Null Result ReportOpen accessMedicine· cited by 19

Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting

Sarah S. Mougalian; Ronda Copher; Jonathan Kish; Lindsay McAllister; Zhixiao Wang; M Broscious; David Garofalo; Janna Radtchenko · 2018 · Cancer Medicine

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

INTRODUCTION: Real-world data are critical to demonstrate the consistency of evidence and external generalizability of randomized controlled trials (RCTs). This study examined characteristics and outcomes of metastatic triple-negative breast cancer (mTNBC) patients treated with eribulin mesylate at community oncology practices in the United States. METHODS: Physicians identified mTNBC patients initiating eribulin between 1 January 2011 and 1 January 2014 and abstracted data into an electronic case report form (eCRF). Eribulin treatment in the metastatic setting was categorized as early use (EU

Abstract by Sarah S. Mougalian; Ronda Copher; Jonathan Kish; Lindsay McAllister; Zhixiao Wang; M Broscious; David Garofalo; Janna Radtchenko, Cancer Medicine (2018) — licensed CC BY 4.0.

Read the full paper (open access)